MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Inmode Ltd

Suletud

SektorTervishoid

14.06 -0.21

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.95

Max

14.15

Põhinäitajad

By Trading Economics

Sissetulek

-4.9M

22M

Müük

-2.4M

93M

P/E

Sektori keskmine

6.702

89.037

Aktsiakasum

0.38

Kasumimarginaal

23.467

Töötajad

599

EBITDA

-5.4M

26M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+22.73% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

10. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

18M

946M

Eelmine avamishind

14.27

Eelmine sulgemishind

14.06

Uudiste sentiment

By Acuity

50%

50%

174 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Inmode Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. jaan 2026, 21:55 UTC

Tulu

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22. jaan 2026, 23:52 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22. jaan 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22. jaan 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22. jaan 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. jaan 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22. jaan 2026, 22:37 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22. jaan 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

22. jaan 2026, 21:44 UTC

Tulu

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22. jaan 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22. jaan 2026, 21:30 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One To Acquire Brex >COF

22. jaan 2026, 21:13 UTC

Tulu

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22. jaan 2026, 21:10 UTC

Tulu

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22. jaan 2026, 21:06 UTC

Tulu

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Rev $15.58B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q EPS $3.26 >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Interest Margin 8.26% >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net $2.13B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Adj EPS $3.86 >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Charge-Offs $3.8B >COF

22. jaan 2026, 21:05 UTC

Tulu

Intuitive Surgical 4Q EPS $2.21 >ISRG

Võrdlus sarnastega

Hinnamuutus

Inmode Ltd Prognoos

Hinnasiht

By TipRanks

22.73% tõus

12 kuu keskmine prognoos

Keskmine 17.33 USD  22.73%

Kõrge 21 USD

Madal 15 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Inmode Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

1

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

14.1 / 14.44Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

174 / 360 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat